Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (May 2023)
29 slides from Cantargia Ab's investor presentation, May 2023
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation May 2023 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Strategy to improve current cancer therapies
Cantargia – Strategy to improve current cancer therapies IL1RAP – A NOVEL TARGET WITH SEVERAL OPPORTUNITIES; CURRENT FOCUS ON SYNERGISTIC COMBINATIONS MDSC – Myeloid-Derived Suppressor Cells 3
Slide 4: New strategy to treat cancer supported by clinical results
New strategy to treat cancer supported by clinical results PROMISING DATA IN PANCREATIC CANCER → Stronger efficacy than expected from chemotherapy → Patients with higher IL1RAP benefit more Nadunolimab Durable response 50% Primary Chemo- Short-term Best change in tumor size tumor therapy response 0%
Slide 5: IL1RAP: Broad application in cancer and autoimmune disease
IL1RAP: Broad application in cancer and autoimmune disease 5
Slide 6: Nadunolimab and Biological Context
NADUNOLIMAB AND BIOLOGICAL CONTEXT
Slide 7: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT IL1RAP-expressing tumors 100 75 50 25 0 l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer cell
Slide 8: Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC
Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC Nadunolimab NADUNOLIMAB COUNTERACTS IMMUNE SUPPRESSION AND POTENTIATES THERAPY ADCC – Antibody-Dependent Cellular Cytotoxicity; TIR – Toll-Interleukin-1 Receptor; NK – Natural Killer 8
Slide 9: Nadunolimab potentiates antitumor activity of chemotherapy
Nadunolimab potentiates antitumor activity of chemo- therapy Nadunolimab IL-1α Tumor growth * 20 100 Relative expression Tumor volume (%) 15 ** Control Docetaxel 10 50 Anti-IL-1β + Docetaxel Nadunolimab + Docetaxel 5 0 0 4 500 Docetaxel (nM) → Nadunolimab blocks both IL-1α and → Docetaxel induces IL
Slide 10: Chemotherapy induces IL-1α and IL-1β in the tumor
Chemotherapy induces IL-1α and IL-1β in the tumor IL-1α IL-1β-converting enzyme Tumor cell region (T) Stromal cell region (S) 6 * Control Gem/Cis 250 ** Control Gem/Cis 2 Positive cells/mm % Positive cells S 200 T T 4 T 150 S S 100 2 S T T 50 T 0 0 l s t ro Ci is l / ro n /C Co Gem nt m Co Ge → Gem/
Slide 11: Targeting IL1RAP uniquely synergizes with chemotherapy
Targeting IL1RAP uniquely synergizes with chemotherapy Tumor growth Body weight 2000 0 Tumor volume (mm ) 3 1500 Vehicle % Change Iso Control -5 Vehicle 1000 Nadunolimab Gem/Cis Gem/Cis ** Nadunolimab+Gem/Cis Nadunolimab+Gem/Cis -10 500 * 0 -15 0 5 10 15 Day post-treatment → Nadunolimab increases ef
Slide 12: Induction of IL1RAP and IL-1α with therapy in NSCLC pts
Induction of IL1RAP and IL-1α with therapy in NSCLC pts Pre-treatment On treatment (Nadunolimab + Gem/Cis) IL1RAP (brown) IL-1α (brown) IL-1ALPHA INDUCED BY CHEMOTHERAPY IN LINE WITH PRECLINICAL FINDINGS; WELL ESTABLISHED DANGER SIGNAL – ACTIVITY BLOCKED BY NADUNOLIMAB 12
Slide 13: PDAC staging and treatment
PDAC staging and treatment Expected number of cases US 2023: 64,000 Stage I - local: 3,200 Stage II - regional LN: 3,200 Stage IV - Stage III - metastatic: locally adv: 32,000 25,600 Stage I Stage II Stage III Stage IV RESECTABLE OR BORDERLINE RESECTABLE DISEASE LOCALLY ADVANCED OR METASTATIC DISEAS
Slide 14: Positive interim data in 1st line pancreatic cancer
Positive interim data in 1st line pancreatic cancer Nadunolimab combination 50% Best change in tumor size with Gem/Abraxane in 1st line PDAC (n=73): 0% → 33% response rate with long PFS and OS -50% → Additional 5 (7%) pts had on- treatment benefit beyond progression -100% iCPD iUPD iSD iPR → Promisi
Slide 15: Strong efficacy in PDAC pts with high tumor IL1RAP levels
Strong efficacy in PDAC pts with high tumor IL1RAP levels IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=27) vs IL1RAP Low (n=19) PDAC pts: → Significantly prolonged OS in ILRAP High vs IL1RAP Low pts (14.2 vs 10.6 months; p=
Slide 16: PDAC pts with high tumor IL1RAP levels have the strongest benefit of nadunolimab combination therapy
OS Nadunolimab/GN IL1RAP High PDAC pts with high tumor IL1RAP levels have the strongest OS Nadunolimab monotherapy Death On study benefit of nadunolimab combination therapy Nadunolimab/GN iUPD/iCPD IL1RAP High Nadunolimab monotherapy iSD Death iPR On study iUPD/iCPD i
Slide 17: Safety profile is manageable and supports MOA
Safety profile is manageable and supports MOA → Neutropenia manageable through G-CSF prophylaxis → In 7 pts given G-CSF prophylaxis, only 1 developed grade 3-4 neutropenia All Patients in All Cycles → Only 1 % peripheral neuropathy grade 3-4 observed (17% in historical controls) 100% n=6 n=15 Grade
Slide 18: Updated efficacy in NSCLC to be presented at ASCO 2023
Updated efficacy in NSCLC to be presented at ASCO 2023 Nadunolimab combination with Gem/Cis in 1st/2nd line NSCLC: Non- → 16 of 30 pts with objective response incl. 2 Non- complete responses All Historical squamous, squamous (n=30) control1,2 historical → One CR achieved on nadunolimab monotherapy (
Slide 19: Promising early safety and efficacy in TNBC
Promising early safety and efficacy in TNBC Nadunolimab combination with Gem/Carbo in 100 % 1st/2nd line metastatic TNBC: Best change in tumor size 15 pts enrolled in the dose-escalation phase 50 % PD → Acceptable safety profile (G-CSF given prophylactically to control neutropenia) SD 0% → 12 pts tr
Slide 20: Key messages
Key messages → Most chemotherapies induce chemoresistance already after Resistant a few months of therapy. Chemotherapy can upregulate tumor both IL-1α and IL-1β. Chemo- therapy → Unlike other IL-1 blocking compounds, nadunolimab blocks both IL-1α and IL-1β signalling and improves chemotherapy effic
Slide 21: CAN10 – Opportunity in Autoimmune/Inflammatory Disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 22: CAN10 – New asset within autoimmunity/inflammation
CAN10 – New asset within autoimmunity/inflammation → IL1RAP-binding antibody potently blocking IL-1, IL-33 and IL-36, without ADCC → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on systemic scle
Slide 23: CAN10 – Promising effects in several preclinical disease models
CAN10 – Promising effects in several preclinical disease models Viral myocarditis Disease severity Autoimmune myocarditis Cardiac function 4 *** 1.1 Ratio to baseline * ** 3 1.0 * mCAN10 Ctrl mCAN10 Score 2 0.9 Anti-IL-1β Ctrl Anti-IL-1β Vehicle 1 0.8 0 0.7 0 10 20 30 40 cle A l 0 ro 1R N1 Day nt hi
Slide 24: CAN10 – Project status
CAN10 – Project status GLP toxicity study – Completed → CAN10 given i.v. once weekly for six weeks at doses up to 50 mg/kg or s.c. at 5 mg/kg → No adverse findings related to CAN10 at/above clinically relevant (pharmacologically active) dose levels Clinical phase I trial – Study start planned for mi
Slide 25: Financials, Milestones & Summary
FINANCIALS, MILESTONES & SUMMARY
Slide 26: Planned next steps
Planned next steps Nadunolimab PDAC NSCLC TNBC CAN10 • Start phase IIb clinical • Evaluate biomarkers in • Randomized phase II • Treatment of first trial in 150-200 pts with 40+ pts treated with stage in TRIFOUR: subject in phase I submssion H2 2023, nadunolimab+chemo to Interim futility analysis cl
Slide 27: Several upcoming value inflection points
Several upcoming value inflection points Newsflow over next quarters Nadunolimab (CAN04) → Update of results for PDAC, NSCLC and TNBC → Start phase IIb trial in PDAC → New preclinical and translational results → New clinical data (efficacy and safety) → CAPAFOUR PDAC FOLFIRINOX → CESTAFOUR Basket tr
Slide 28: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents 353 MSEK (~$33M) at end of Q1 2023 Current owners (Mar 31, 2023) → Runway until mid-2024 4th AP fund 8.8% Alecta 7.3% → Market cap approx. 0.8 BSEK, 75 MUSD May 26, 2023 1st AP fund 6.3% Avanza Pension 5.1% Six Sis
Slide 29: Cantargia: Investment highlights
Cantargia: Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO ADDRESS CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • Potential to breakdown resistance to cancer treatment, enabled by unique dual action approach – nadunolimab • Additional key target for inf